Skip to main content

Table 3 Comparison of risk of antituberculosis-drug induced liver injury (antiTB-DILI) between two treatment groups: Intention-to-treat approach

From: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

  Placebo Silymarin p-value RR RD NNT
(N = 28) (N = 27) (95 % CI)
DILI 9 (32.1) 1 (3.7) 0.012 0.12 (0.02, 0.85) 0.28 (0.10, 0.47) 3.50 (2.11, 2.37)
Non-DILI 19 (67.9) 26 (96.3)   1   
  1. DILI, drug induced liver injury; RR, risk ratio; RD, risk difference; NNT, number need to treat
  2. Categorical variables reported as N (%)